AU2001238491A1 - Method of making embryoid bodies from primate embryonic stem cells - Google Patents
Method of making embryoid bodies from primate embryonic stem cellsInfo
- Publication number
- AU2001238491A1 AU2001238491A1 AU2001238491A AU2001238491A AU2001238491A1 AU 2001238491 A1 AU2001238491 A1 AU 2001238491A1 AU 2001238491 A AU2001238491 A AU 2001238491A AU 2001238491 A AU2001238491 A AU 2001238491A AU 2001238491 A1 AU2001238491 A1 AU 2001238491A1
- Authority
- AU
- Australia
- Prior art keywords
- primate
- cell
- cells
- clumps
- embryoid bodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Description
METHOD OF MAKING EMBRYOID BODIES FROM PRIMATE EMBRYONIC STEM CELLS CROSS REFERENCES TO RELATED APPLICATIONS Not applicable. STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH
The work with the non-human primate cells described below was supported by a grant with United States government support awarded by the following agency: NIH RR11571. The United States has certain rights in this invention. No U.S. government funds were used for the work with human cells described herein.
BACKGROUND OF THE INVENTION Undifferentiated primate embryonic stem ("ES") cells can be cultured indefinitely and yet maintain the potential to form differentiated cells of the body. See U.S. patent 5,843,780; J. Thomson, et al. , 282 Science 1145-1147 (1998); and J. Thomson, et a , 38 Biology 133- 165 (1998). The disclosure of these publications and of all other publications referred to herein are incorporated by reference as if fully set forth herein.
Primate ES cells thus provide an exciting new model for understanding the differentiation and function of human tissue, and offer new strategies for drug discovery and testing. They also promise new therapies based on the transplantation of ES cell-derived tissues. For example, human and rhesus monkey ES cells injected into immunocompromised mice form benign teratomas with advanced differentiated derivatives representing all three embryonic germ layers. Easily identified differentiated cells in human ES cell teratomas include smooth muscle, striated muscle, bone, cartilage, gut and respiratory epithelium, keratinizing squamous epithelium, hair, neural epithelium, and ganglia.
Human and non-human primate ES cell lines provide a particularly powerful new model for understanding normal human development and thus also for understanding
abnormal human development. Because of the potential risk to the resulting child, experimental manipulation of the post-implantation human embryo is ethically unacceptable and as a result functional studies on human embryos are lacking. Consequently, what is known about human development in the early post-implantation period is based almost entirely on static histological sections of a few human embryos and on analogy to experimental embryology studies of the mouse. However, early mouse and primate development differ significantly. For example, human and mouse embryos differ in the timing of embryonic genome expression, in the formation, structure, and function of the fetal membranes and placenta and in the formation of an embryonic disc instead of an egg cylinder. The earliest events of human development are critically involved in human infertility, pregnancy loss, and birth defects. Primate ES cells offer a new window for understanding these early human developmental events and for understanding the pathogenesis of developmental failures.
Primate ES cells also provide a potentially unlimited source of differentiated, euploid, non- transformed cells for investigators interested in the normal function and pathology of specific differentiated primate cells. Such purified populations of specific ES cell-derived cells will also likely be useful for drug discovery, toxicity screens, and will provide a source of cells for transplantation.
For tissues such as the heart that completely lack a tissue-specific stem cell, primate ES cells will prove even more valuable. Primate ES cells also offer the promise of new transplantation therapies. When disease results from the destruction or dysfunction of a limited number of cell types, such as in Parkinson's disease (dopa inergic neurons) , or juvenile onset diabetes
mellitus (pancreatic β-islet cells) , the replacement of those specific cell types by ES cell derivatives could offer potentially life long treatment.
To accomplish these goals, it is desirable to more efficiently differentiate ES cells to specific lineages. Considerable progress in causing non-primate ES cell differentiation to neural, hematopoietic, and cardiac tissue has been made. See e.g. T. Doetschman, et al . , 87 J. Embry. And Exper. Morph. 27-45 (1985); G. Keller, 7 Current Op. In Cell Biol. 862-869 (1995); U.S. patent 5,914,268. In each of these examples, ES cells were first formed into "embryoid bodies", three-dimensional ES cell aggregates that facilitate subsequent differentiation . However, analogous experiments on primate ES cells demonstrated that embryoid body formation by conventional murine protocols fail. In such conventional protocols ES cells are dispersed to single cells, and either allowed to aggregate into embryoid bodies under conditions that prevent cell attachment to the substrate, or the ES cells are allowed to grow into embryoid bodies from single cells or clusters suspended in methylcellulose. We have learned that primate ES cells die rapidly when dispersed to single cells if attachment is prevented, so they do not successfully aggregate, and they therefore do not grow out from clones in methylcellulose.
It can therefore be seen that a need exists for improved methods for producing primate embryoid bodies, and differentiated cells derived therefrom. BRIEF SUMMARY OF THE INVENTION
The present invention provides a method for producing primate embryoid bodies from colonies of primate embryonic stem cells that are adhering to a substrate. One removes the adhering colonies of the embryonic stem cells from the substrate in clumps. One
then incubates the clumps in a container under conditions in which the clumps are essentially inhibited from attaching to the container and coalesce into embryoid bodies. For purposes of this application, a clump is a grouping of two or more stem cells, preferably a clump large enough to be visible to the naked eye.
In one preferred form the removal step is in the presence of an agent that promotes disassociation of the clumps from the substrate as clumps. A purely chemical agent such as Versene® calcium disodium EDTA chelating agent can be used. However, more preferred is a proteinase that preferentially acts on the extra cellular matrix such as dispase, collagenase, catalase, neura inidase, pancreatin, pancreatic elastase or trypsin. If trypsin is used the removal step must be conducted quickly and at relatively low concentrations in order to prevent the trypsin from also destroying the clumps. Enzyme EDTA mixes can also be used to advantage. In another form the removal step involves mechanically scraping the clumps from the substrate as clumps .
In another aspect the incubation step can be conducted by agitating the container (e.g. by gently rocking, shaking, or vibrating it) , the container for the incubation step can be a non-attaching bacterial grade culture plastic, and/or the incubation step can be in the presence of a serum-free medium which lacks serum attachment factors .
In another aspect the invention provides primate embryoid bodies that have been derived (directly or indirectly) using the above methods.
In still another aspect the invention provides differentiated cells derived (directly or indirectly) from the embryoid bodies. In accordance with the present invention, primate ES
cells that have been cultured under standard conditions (see e.g. U.S. patent 5,843,780) are permitted to overgrow, pile up and/or otherwise closely associate in clumps on a substrate (e.g. a plastic tissue culture plate with standard feeder layer) . They are then removed as clumps from the substrate (e.g. by incubating the colonies with an enzyme which attacks the ES cell colony' s attachment to the substrate more strongly than ES cell attachments with ES cells) . In such a case the enzyme could be dispase at a concentration of about 10 mg/ml .
Alternatively, the clumps could be removed as clumps by mechanically scraping with a micropipette, cell scraper, or the like. The essentially intact colonies are then incubated under non-attaching conditions (preferably continuous rocking of the culture dish, culture on non-attaching bacterial grade culture plastic, and/or continuous culture in the presence of serum-free medium which lacks serum attachment factors) . The colonies can then quickly coalesce into compact embryoid bodies, which can thereafter be allowed to differentiate either in continuous suspension, or after re-attachment to a substrate. Such embryoid bodies can be used to derive differentiated derivatives of endoderm, mesoderm, and ectoderm, and for obtaining other desired lineages.
It is an advantage of the present invention that it provides effective methods of forming primate embryoid bodies from primate embryonic stem cell lines. Another advantage of the present invention is to provide primate embryoid bodies suitable for differentiation into other primate cell types. Other features and advantages of the present invention will become apparent after study of the specification and claims which follow.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
Formation Of Embryoid Bodies Primate embryonic stem cells (e.g. rhesus or human - U.S. patent 5,843,780; J. Thomson, et al. , 282 Science 1145-1147 (1998)) are cultured on mitotically inactivated (3000 rads g-radiation) mouse embryonic fibroblasts,
4 prepared at 5x10 cells/cm on tissue culture plastic previously treated by overnight incubation with 0.1% gelatin. E. Robertson, Embryo-derived Stem Cell Lines. In: Teratocarcinomas And Embryonic Stem Cells: A
Practical Approach IRL Press: Washington, D.C., 71-112 (1987). Culture medium consists of 79% Dulbecco's modified Eagle medium (DMEM; 4500 mg of glucose per liter; without sodium pyruvate) , 20% fetal bovine serum (FBS) , 0.1 mM 2-mercaptoethanol, 1 mM L-glutamine and 1% nonessential amino acid stock (GIBCO) .
One allows colonies to form clumps over a period of hours. ES cell colonies can then be removed from the tissue culture plate using physical or chemical methods that keep the ES cells in clumps.
For dispase or collagenase removal of ES cell colonies from the culture plate, the culture medium is removed from the ES cells. Dispase (10 mg/ml in ES culture medium) or collagenase (1 mg/ml solution in DMEM or other basal medium) is added to the culture plate. The culture plates are returned to the incubator for 10-15 minutes .
After dispase treatment the colonies can either be washed off the culture dishes or will become free of the tissue culture plate with gentle agitation. After collagenase treatment the cells can be scraped off the culture dish with a 5 ml glass pipette. Some dissociation of the colonies occurs, but this is not sufficient to individualize the cells. After chemical removal of the cells from the tissue culture plate, the cell suspension
is centrifuged gently for 5 minutes, the supernatant is removed and discarded, the cells are rinsed, and the cells are resuspended in culture medium with or without serum. Mechanical removal of the cells is achieved by using a pulled glass pipette to scrape the cells from the culture plate. Cell clumps can be immediately resuspended, without centrifugation, in fresh tissue culture medium. Once colonies are removed from the tissue culture plate, the ES cells should remain in suspension during further embryoid body formation. This can be achieved by, for example, gently and continuously rocking the cell suspension. Cell suspensions are aliquoted into wells of 6-well tissue culture dishes, placed inside a sealed, humidified isolation chamber, gassed with 5% C02, 5%02 and 90%N2 and placed on a rocker (Red Rocker, Hoefer Scientific Instruments) . The rocker is housed inside an incubator maintained at 37°C. The culture plates can be rocked continuously for at least 48 hours and up to 14 days .
Every 2 days the plates are removed from the rocking device, the culture medium is removed, and fresh culture medium is added to the cells. The culture dishes are then returned to the rocking environment. Cells will also remain in suspension when cultured in suspension culture dishes (Nunc) without rocking, or when cultured in the absence of serum, which provides attachment factors. All cells must be cultured at 37°C, in a humidified, controlled gas atmosphere (either 5% C02, 5% 02 and 90% N2 or 5% C02 in air) .
Following culture in suspension for up to 11 days, embryoid bodies are dispensed by mechanical or chemical means and can be allowed to reattach to tissue culture plates treated with gelatin or matrix, in ES medium.
Displaced, plated embryoid bodies will form flattened monolayers and can be maintained by replacing medium every 2 days .
Analysis Of Embryoid Bodies And Differentiated Cells We used immunofluorescent antibody staining up to 7 days after plating to confirm the existence of cells of the neural phenotype . Cells were fixed in 30% methanol/10% acetic acid before incubation with antibodies. Antibodies that were used are as follows: rabbit anti-bovine GFAP (DAKO) , anti-Forse-1
(Developmental Studies Hybridoma Bank) , anti-bovine MAP-2 (Roche) , anti-human NCAM/CD56 (DAKO) and anti-01 (provided by S.-C. Zhang, University of Wisconsin). All primary antibodies are mouse monoclonals except anti- GFAP. Secondary antibodies, FITC-conjugated goat anti- mouse IgG and biotin-conjugated goat anti-rabbit, as well as AMCA-conjugated streptavidin were purchased from Jackson ImmunoResearch.
The Forse-1 antibody recognizes phosphacan, a brain- specific chondroitin sulfate proteoglycan that binds neural cell adhesion molecules in the embryonic CNS of both humans and rodents. K. Allendorfer et al . , 6 Mol. And Cell. Neuro. 381-395 (1995); S. Tole et al*., 15 J. Neuro. 957-969 (1995) . The 01 antibody identifies pro- oligodendrocytes present from day 3 in embryonic mouse brain cultures. M. Schachner et al . , 83 Dev. Biol. 328- 338 (1981); I. Sommer, et a , 83 Dev. Biol. 311-327 (1981) .
Within three days of plating, the neural precursors, stained by Forse-1 and 01, were observed. The Forse-1 antibody stained numerous rounded cells, whereas very sparse, flattened cells with extensive projections were stained with the anti-01 antibody.
Neurons and glial were detected, 3 days and later after plating, by positive staining of neural cell
adhesion molecule (NCAM)/CD56 (Figure 3), microtubule- associated protein-2 (MAP-2) (Figure 3) , βlll-tubulin and glial fibrillary acidic protein (GFAP) . NCAM is a cell adhesion molecule thought to be important in cell-cell interactions within the neuroepithelium. B. Cunningham, et a , 236 Science 799-806 (1987); J. Ritz, et a , 42 Adv. Immuno. 181-211 (1988) . MAP-2 plays an important role in brain microtubule assembly. βlll-tubulin is a neuron-specific marker, and glial fibrillary acidic protein (GFAP) is an astrocyte marker.
Differentiation Into Lineages Embryoid bodies can be differentiated into a variety of desired lineages. For example the embryoid bodies could be used to derive hematopoietic cells using techniques analogous to those used for mouse in M. Wiles et al. Ill Development 259-267 (1991) . In this regard one could plate the embryoid bodies in serum-containing medium in the presence of 2 i.u./ml erythropoietin or IL- 3. If cardiac lineages are desired one could use techniques analogous to T. Doetschman et al . , 87 J. Embry. Exper. Morph. 27-45 (1985) . One could plate the •bodies in serum-containing medium with no additives. To develop neural lineages one could plate the embryoid bodies in the presence of 20 ng/ml fibroblast growth factor plus 20 ng/ml epidermal growth factor. This is analogous to techniques described in B. Reynolds et alj., 255 Science 5052 (1992) .
The present invention thus provides an effective method for making primate embryoid bodies from primate ES cells. While the above work was focused on rhesus and human embryonic stem cells (and neural cells derived therefrom via these embryoid bodies) , the techniques described herein should work broadly for primate embryonic stem cells and other cell types. Further,
while specific techniques for clump removal have been discussed, the invention is not limited to those alone. Rather, other techniques for removing the cells in clumps from the substrate should work. Thus, the invention is not limited to the specific embodiments described herein. Rather, the claim should be looked to in order to judge the full scope of the invention.
Industrial Applicability The present invention provides a supply of human and other primate embryoid bodies suitable for research, medical purposes, and differentiation into lineages.
Claims (15)
1. A method for producing primate embryoid bodies from colonies of primate embryonic stem cells that are adhering to a substrate, the method comprising: removing the adhering colonies of the embryonic stem cells from the substrate in clumps; and then incubating the clumps in a container under conditions in which the clumps are essentially inhibited from attaching to the container and coalesce into embryoid bodies.
2. The method of claim 1, wherein the removal step is conducted in the presence of an enzyme that promotes disassociation of the clumps as clumps from the substrate.
3. The method of claim 2, wherein the enzyme is dispase .
4. The method of claim 1, wherein the removal step is conducted in the presence of a chelating agent.
5. The method of claim 1, wherein the removal step comprises mechanically scraping the clumps from the substrate.
6. The method of claim 1, wherein the removal step is conducted in the presence of trypsin, calcium and magnesium.
7. The method of claim 1, wherein the incubation step comprises agitating the container.
8. The method of claim 1, wherein the incubation step is conducted in a container made of plastic.
9. The method of claim 1, wherein the incubation step is conducted in the presence of a serum-free medium.
10. The method of claim 1, wherein the primate embryonic stem cells are human embryonic stem cells and the primate embryoid bodies are human embryoid bodies.
11. A primate embryoid body derived from the method of claim 1.
12. The primate embryoid body of claim 11, wherein the embryoid body is a human embryoid body.
13. A differentiated primate cell derived from the embryoid body of claim 11.
14. The differentiated primate cell of claim 13, wherein the cell is a human cell.
15. The differentiated primate cell of claim 14, wherein the cell is a human neural cell.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09510444 | 2000-02-21 | ||
US09/510,444 US6602711B1 (en) | 2000-02-21 | 2000-02-21 | Method of making embryoid bodies from primate embryonic stem cells |
PCT/US2001/005252 WO2001062899A2 (en) | 2000-02-21 | 2001-02-20 | Method of making embryoid bodies from primate embryonic stem cells |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2006203588A Division AU2006203588A1 (en) | 2000-02-21 | 2006-08-18 | Method of making embryoid bodies from primate embryonic stem cells |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2001238491A1 true AU2001238491A1 (en) | 2001-11-15 |
AU2001238491B2 AU2001238491B2 (en) | 2006-05-18 |
Family
ID=24030756
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU3849101A Pending AU3849101A (en) | 2000-02-21 | 2001-02-20 | Method of making embryoid bodies from primate embryonic stem cells |
AU2001238491A Expired AU2001238491B2 (en) | 2000-02-21 | 2001-02-20 | Method of making embryoid bodies from primate embryonic stem cells |
AU2006203588A Abandoned AU2006203588A1 (en) | 2000-02-21 | 2006-08-18 | Method of making embryoid bodies from primate embryonic stem cells |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU3849101A Pending AU3849101A (en) | 2000-02-21 | 2001-02-20 | Method of making embryoid bodies from primate embryonic stem cells |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2006203588A Abandoned AU2006203588A1 (en) | 2000-02-21 | 2006-08-18 | Method of making embryoid bodies from primate embryonic stem cells |
Country Status (15)
Country | Link |
---|---|
US (2) | US6602711B1 (en) |
EP (1) | EP1257634A2 (en) |
JP (1) | JP5339661B2 (en) |
KR (1) | KR100812856B1 (en) |
CN (1) | CN1404526A (en) |
AU (3) | AU3849101A (en) |
BR (1) | BRPI0108436B8 (en) |
CA (1) | CA2400158C (en) |
HK (1) | HK1052951A1 (en) |
IL (2) | IL151176A0 (en) |
IS (1) | IS6514A (en) |
MX (1) | MXPA02008054A (en) |
NO (1) | NO20023949L (en) |
NZ (1) | NZ520700A (en) |
WO (1) | WO2001062899A2 (en) |
Families Citing this family (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6667176B1 (en) * | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
IL129966A (en) * | 1999-05-14 | 2009-12-24 | Technion Res & Dev Foundation | ISOLATED HUMAN EMBRYOID BODIES (hEB) DERIVED FROM HUMAN EMBRYONIC STEM CELLS |
US7015037B1 (en) | 1999-08-05 | 2006-03-21 | Regents Of The University Of Minnesota | Multiponent adult stem cells and methods for isolation |
US8252280B1 (en) | 1999-08-05 | 2012-08-28 | Regents Of The University Of Minnesota | MAPC generation of muscle |
US10638734B2 (en) | 2004-01-05 | 2020-05-05 | Abt Holding Company | Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
US20050042749A1 (en) * | 2001-05-16 | 2005-02-24 | Carpenter Melissa K. | Dopaminergic neurons and proliferation-competent precursor cells for treating Parkinson's disease |
US6602711B1 (en) | 2000-02-21 | 2003-08-05 | Wisconsin Alumni Research Foundation | Method of making embryoid bodies from primate embryonic stem cells |
WO2001088104A2 (en) | 2000-05-17 | 2001-11-22 | Geron Corporation | Neural progenitor cell populations |
US7250294B2 (en) * | 2000-05-17 | 2007-07-31 | Geron Corporation | Screening small molecule drugs using neural cells differentiated from human embryonic stem cells |
US7045353B2 (en) | 2000-08-01 | 2006-05-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Directed differentiation of human embryonic cells |
JP2005503759A (en) * | 2001-01-24 | 2005-02-10 | アメリカ合衆国 | Differentiation of stem cells into pancreatic endocrine cells |
EP1367899A4 (en) | 2001-02-14 | 2004-07-28 | Leo T Furcht | Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
US20030211605A1 (en) * | 2001-05-01 | 2003-11-13 | Lee Sang-Hun | Derivation of midbrain dopaminergic neurons from embryonic stem cells |
IL159895A0 (en) * | 2001-07-20 | 2004-06-20 | Technion Res & Dev Foundation | Methods of generating human cardiac cells and tissues and uses thereof |
JP4317337B2 (en) * | 2001-10-16 | 2009-08-19 | 株式会社リプロセル | Cell line passage enzyme solution and method for culturing and proliferating primate embryonic stem cells using the same |
US6759244B2 (en) | 2001-11-08 | 2004-07-06 | Art Institute Of New York And New Jersey, Inc. | Composite blastocysts (CBs) from aggregates of dissociated cells of non-viable pre-embryos |
US7799324B2 (en) | 2001-12-07 | 2010-09-21 | Geron Corporation | Using undifferentiated embryonic stem cells to control the immune system |
US20050090004A1 (en) * | 2003-01-16 | 2005-04-28 | Sayre Chauncey B. | Stem cell maturation for all tissue lines |
US20030134422A1 (en) * | 2002-01-16 | 2003-07-17 | Sayre Chauncey Bigelow | Stem cell maturation for all tissue lines |
US20050170506A1 (en) * | 2002-01-16 | 2005-08-04 | Primegen Biotech Llc | Therapeutic reprogramming, hybrid stem cells and maturation |
US20030162290A1 (en) * | 2002-01-25 | 2003-08-28 | Kazutomo Inoue | Method for inducing differentiation of embryonic stem cells into functioning cells |
US7160719B2 (en) | 2002-06-07 | 2007-01-09 | Mayo Foundation For Medical Education And Research | Bioartificial liver system |
WO2004039966A1 (en) * | 2002-10-31 | 2004-05-13 | Pfizer Products Inc. | Suspension method for producing embryoid bodies, and compositions and methods related thereto |
US7947499B2 (en) * | 2002-11-29 | 2011-05-24 | Technion Research & Development Foundation Ltd. | Method of dynamically culturing embryonic stem cells |
EP1613726A4 (en) * | 2003-03-12 | 2007-08-22 | Reliance Life Sciences Pvt Ltd | Derivation of terminally differentiated dopaminergic neurons from human embryonic stem cells |
US9567591B2 (en) | 2003-05-15 | 2017-02-14 | Mello Biotechnology, Inc. | Generation of human embryonic stem-like cells using intronic RNA |
US20090203141A1 (en) * | 2003-05-15 | 2009-08-13 | Shi-Lung Lin | Generation of tumor-free embryonic stem-like pluripotent cells using inducible recombinant RNA agents |
CN1788079A (en) * | 2003-06-13 | 2006-06-14 | 湖南惠霖生命科技有限公司 | Method for separating and cultiviting human multifunctional embryo stem cell |
US8148152B2 (en) * | 2003-07-08 | 2012-04-03 | Axiogenesis Ag | Method for the preparation of embryoid bodies (EBs) and uses thereof |
US7820439B2 (en) * | 2003-09-03 | 2010-10-26 | Reliance Life Sciences Pvt Ltd. | In vitro generation of GABAergic neurons from pluripotent stem cells |
WO2005049812A1 (en) * | 2003-11-19 | 2005-06-02 | Australian Stem Cell Centre Limited | Methods for producing blood products from pluripotent cells in cell culture |
US20080026460A1 (en) * | 2006-06-20 | 2008-01-31 | Palecek Sean P | Method for culturing stem cells |
US20070269412A1 (en) * | 2003-12-02 | 2007-11-22 | Celavie Biosciences, Llc | Pluripotent cells |
ES2579804T3 (en) * | 2003-12-02 | 2016-08-16 | Celavie Biosciences, Llc | Compositions and methods for the propagation of neural progenitor cells |
EP4248752A3 (en) | 2004-01-23 | 2024-01-03 | President And Fellows Of Harvard College | Improved modalities for the treatment of degenerative diseases of the retina |
US7794704B2 (en) | 2004-01-23 | 2010-09-14 | Advanced Cell Technology, Inc. | Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration |
JP4491014B2 (en) * | 2004-04-01 | 2010-06-30 | ウイスコンシン アラムニ リサーチ ファンデーション | Differentiation of stem cells into endoderm and pancreatic lineages |
DK1740945T3 (en) | 2004-04-07 | 2019-01-21 | Ncardia Ag | KKE-INVASIVE, IN-VITRO FUNCTIONAL TISSUE TEST SYSTEMS |
JP4814875B2 (en) | 2004-05-11 | 2011-11-16 | アキシオジェネシス エージー | Assay for drug discovery based on in vitro differentiated cells |
US20050277124A1 (en) | 2004-06-10 | 2005-12-15 | White Steven M | Cardiac conduction system cells and uses thereof |
WO2005123902A1 (en) * | 2004-06-18 | 2005-12-29 | Riken | Method of inducing the differentiation of embryonic stem cells into nerve by serum-free suspension culture |
US20070148767A1 (en) * | 2005-12-28 | 2007-06-28 | Mei-Ju Yang | Method of forming multicellular spheroids from the cultured cells |
KR100785049B1 (en) | 2006-01-11 | 2007-12-12 | 한국과학기술연구원 | Method and apparatus for forming and growing embryoid body |
US20070238169A1 (en) * | 2006-04-11 | 2007-10-11 | The Board Of Trustees Of The Leland Stanford Junior University | Cell sorter and culture system |
KR20170102040A (en) | 2006-04-14 | 2017-09-06 | 아스텔라스 인스티튜트 포 리제너러티브 메디슨 | Hemangio-colony forming cells |
EP2087101A2 (en) | 2006-11-24 | 2009-08-12 | Regents of the University of Minnesota | Endodermal progenitor cells |
WO2008137115A1 (en) | 2007-05-03 | 2008-11-13 | The Brigham And Women's Hospital, Inc. | Multipotent stem cells and uses thereof |
US20110236971A2 (en) | 2007-09-25 | 2011-09-29 | Maksym Vodyanyk | Generation of Clonal Mesenchymal Progenitors and Mesenchymal Stem Cell Lines Under Serum-Free Conditions |
WO2009051671A1 (en) | 2007-10-12 | 2009-04-23 | Advanced Cell Technology, Inc. | Improved methods of producing rpe cells and compositions of rpe cells |
WO2009134409A2 (en) * | 2008-04-30 | 2009-11-05 | Sanbio, Inc. | Neural regenerating cells with alterations in dna methylation |
CN102083963A (en) * | 2008-05-06 | 2011-06-01 | 先进细胞技术公司 | Hemangio colony forming cells and non-engrafting hemangio cells |
CN104328087A (en) | 2008-05-06 | 2015-02-04 | 先进细胞技术公司 | Methods for producing enucleated erythroid cells derived from pluripotent stem cells |
US9394538B2 (en) | 2008-05-07 | 2016-07-19 | Shi-Lung Lin | Development of universal cancer drugs and vaccines |
US8956867B2 (en) | 2008-11-07 | 2015-02-17 | Wisconsin Alumni Research Foundation | Method for culturing stem cells |
US20110243898A1 (en) * | 2008-12-10 | 2011-10-06 | The University Of Louisville Research Foundation, Inc. | Somatic cell-derived pluripotent cells and methods of use therefor |
US20100209399A1 (en) * | 2009-02-13 | 2010-08-19 | Celavie Biosciences, Llc | Brain-derived stem cells for repair of musculoskeletal system in vertebrate subjects |
CN102348794B (en) * | 2009-03-09 | 2014-09-03 | 东洋制罐株式会社 | Cell culture method, cell culture device, method for counting subject matters to be counted in container and device for counting |
EP2405957B1 (en) | 2009-03-13 | 2020-12-23 | Mayo Foundation For Medical Education And Research | Bioartificial liver |
ES2550202T3 (en) * | 2009-08-03 | 2015-11-05 | Recombinetics, Inc. | Methods and compositions for targeted gene modification |
JP5902092B2 (en) * | 2009-10-19 | 2016-04-13 | セルラー ダイナミクス インターナショナル, インコーポレイテッド | Cardiomyocyte generation |
KR102073730B1 (en) | 2009-11-17 | 2020-02-05 | 아스텔라스 인스티튜트 포 리제너러티브 메디슨 | Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells |
JP5827220B2 (en) | 2010-01-22 | 2015-12-02 | 国立大学法人京都大学 | Method for improving the efficiency of establishment of induced pluripotent stem cells |
US8558913B2 (en) * | 2010-02-08 | 2013-10-15 | Apple Inc. | Capture condition selection from brightness and motion |
WO2011116361A1 (en) * | 2010-03-19 | 2011-09-22 | Amerstem, Inc. | Compositions and manufacture of mammalian stem cell-based cosmetics |
AU2011268056B2 (en) | 2010-06-18 | 2014-04-24 | Cellular Dynamics International, Inc. | Cardiomyocyte medium with dialyzed serum |
US9181529B2 (en) | 2010-10-19 | 2015-11-10 | Cellular Dynamics International, Inc. | Titration of differentiation medium components |
EP2630232A4 (en) | 2010-10-22 | 2014-04-02 | Biotime Inc | Methods of modifying transcriptional regulatory networks in stem cells |
WO2012074117A1 (en) | 2010-12-03 | 2012-06-07 | 国立大学法人京都大学 | Efficient method for establishing artificial pluripotent stem cells |
EP2801377B1 (en) | 2011-03-04 | 2019-08-07 | The Regents of The University of California | Hydrogel comprising cells for local release of growth factors to mediate motor recovery after stroke |
US9487752B2 (en) | 2011-03-30 | 2016-11-08 | Cellular Dynamics International, Inc. | Priming of pluripotent stem cells for neural differentiation |
CA2832356C (en) | 2011-04-06 | 2017-12-19 | Sanbio, Inc. | Methods and compositions for modulating peripheral immune function |
WO2013010045A1 (en) | 2011-07-12 | 2013-01-17 | Biotime Inc. | Novel methods and formulations for orthopedic cell therapy |
CN102329770A (en) * | 2011-09-23 | 2012-01-25 | 安徽农业大学 | Improved manufacturing method for mouse embryonic bodies |
US20140178988A1 (en) | 2012-10-08 | 2014-06-26 | Biotime, Inc. | Differentiated Progeny of Clonal Progenitor Cell Lines |
WO2014100779A1 (en) | 2012-12-21 | 2014-06-26 | Advanced Cell Technology, Inc. | Methods ofr production of platelets from pluripotent stem cells and compositions thereof |
EP3006559B1 (en) | 2013-05-31 | 2019-11-06 | iHeart Japan Corporation | Layered cell sheet incorporating hydrogel |
CN105473134B (en) | 2013-06-05 | 2021-04-27 | 再生疗法有限公司 | Compositions and methods for induced tissue regeneration in mammalian species |
US11078462B2 (en) | 2014-02-18 | 2021-08-03 | ReCyte Therapeutics, Inc. | Perivascular stromal cells from primate pluripotent stem cells |
US10240127B2 (en) | 2014-07-03 | 2019-03-26 | ReCyte Therapeutics, Inc. | Exosomes from clonal progenitor cells |
TW202344686A (en) | 2015-10-30 | 2023-11-16 | 美國加利福尼亞大學董事會 | Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells |
CA3007733A1 (en) | 2015-12-07 | 2017-06-15 | Biotime, Inc. | Methods for the re-derivation of diverse pluripotent stem cell-derived brown fat cells |
CN109069870B (en) | 2016-02-24 | 2022-04-29 | 洛克菲勒大学 | Embryonic cell-based therapeutic candidate screening systems, models for huntington's disease and uses thereof |
US11572544B2 (en) | 2017-06-14 | 2023-02-07 | The Children's Medical Center Corporation | Hematopoietic stem and progenitor cells derived from hemogenic endothelial cells by episomal plasmid gene transfer |
WO2020040247A1 (en) * | 2018-08-24 | 2020-02-27 | 日産化学株式会社 | Method for producing polymer used for cell culture base film, and cell culture vessel |
CN111378613B (en) * | 2018-12-27 | 2024-01-09 | 深圳华大生命科学研究院 | Amphibious animal cell dissociation kit |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5196315A (en) * | 1990-05-01 | 1993-03-23 | The Johns Hopkins University | Human neuronal cell line |
JPH0638742A (en) * | 1992-04-06 | 1994-02-15 | N T Sci:Kk | Method for culturing animal embryonic stem cell |
US5453357A (en) | 1992-10-08 | 1995-09-26 | Vanderbilt University | Pluripotential embryonic stem cells and methods of making same |
US5914268A (en) | 1994-11-21 | 1999-06-22 | National Jewish Center For Immunology & Respiratory Medicine | Embryonic cell populations and methods to isolate such populations |
US5874301A (en) | 1994-11-21 | 1999-02-23 | National Jewish Center For Immunology And Respiratory Medicine | Embryonic cell populations and methods to isolate such populations |
US5843780A (en) * | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
WO1999027076A1 (en) | 1997-11-25 | 1999-06-03 | Arc Genomic Research | Pluripotent embryonic stem cells and methods of obtaining them |
DE19756864C5 (en) * | 1997-12-19 | 2014-07-10 | Oliver Brüstle | Neural precursor cells, methods for their production and their use for the therapy of neural defects |
IL129966A (en) * | 1999-05-14 | 2009-12-24 | Technion Res & Dev Foundation | ISOLATED HUMAN EMBRYOID BODIES (hEB) DERIVED FROM HUMAN EMBRYONIC STEM CELLS |
US6280718B1 (en) * | 1999-11-08 | 2001-08-28 | Wisconsin Alumni Reasearch Foundation | Hematopoietic differentiation of human pluripotent embryonic stem cells |
US6602711B1 (en) | 2000-02-21 | 2003-08-05 | Wisconsin Alumni Research Foundation | Method of making embryoid bodies from primate embryonic stem cells |
-
2000
- 2000-02-21 US US09/510,444 patent/US6602711B1/en not_active Expired - Lifetime
-
2001
- 2001-02-20 EP EP01910936A patent/EP1257634A2/en not_active Withdrawn
- 2001-02-20 MX MXPA02008054A patent/MXPA02008054A/en active IP Right Grant
- 2001-02-20 AU AU3849101A patent/AU3849101A/en active Pending
- 2001-02-20 CN CN01805291A patent/CN1404526A/en active Pending
- 2001-02-20 KR KR1020027010830A patent/KR100812856B1/en active IP Right Grant
- 2001-02-20 AU AU2001238491A patent/AU2001238491B2/en not_active Expired
- 2001-02-20 NZ NZ520700A patent/NZ520700A/en not_active IP Right Cessation
- 2001-02-20 BR BRPI0108436-4 patent/BRPI0108436B8/en not_active IP Right Cessation
- 2001-02-20 CA CA002400158A patent/CA2400158C/en not_active Expired - Lifetime
- 2001-02-20 JP JP2001562673A patent/JP5339661B2/en not_active Expired - Lifetime
- 2001-02-20 WO PCT/US2001/005252 patent/WO2001062899A2/en active IP Right Grant
- 2001-02-20 IL IL15117601A patent/IL151176A0/en active IP Right Grant
-
2002
- 2002-08-20 NO NO20023949A patent/NO20023949L/en unknown
- 2002-08-20 IS IS6514A patent/IS6514A/en unknown
-
2003
- 2003-07-15 HK HK03105100.3A patent/HK1052951A1/en unknown
- 2003-08-01 US US10/632,399 patent/US7220584B2/en not_active Expired - Lifetime
-
2006
- 2006-08-18 AU AU2006203588A patent/AU2006203588A1/en not_active Abandoned
-
2010
- 2010-10-14 IL IL208748A patent/IL208748A/en active IP Right Grant
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6602711B1 (en) | Method of making embryoid bodies from primate embryonic stem cells | |
AU2001238491A1 (en) | Method of making embryoid bodies from primate embryonic stem cells | |
US11898161B2 (en) | Stem cell culture medium and method | |
Sjögren‐Jansson et al. | Large‐scale propagation of four undifferentiated human embryonic stem cell lines in a feeder‐free culture system | |
JP5128946B2 (en) | Feeder-independent long-term culture of embryonic stem cells | |
IL179726A (en) | METHOD FOR ENHANCING DIFFERENTIATION OF hES CELLS INTO CARDIOMYOCYTES | |
Raya et al. | Generation of cardiomyocytes from new human embryonic stem cell lines derived from poor-quality blastocysts | |
CN101443445B (en) | Culture system and method for propagation of human blastocyst-derived stem cells | |
KAWAMORTTA et al. | In vitro differentiation of mouse embryonic stem cells after activation by retinoic acid | |
JP5363820B2 (en) | Culture system and method for growing stem cells from human blastocysts | |
WO2005059116A1 (en) | Methods for clonal derivation of human blastocyst-derived stem cell lines |